$377 Million is the total value of Ghost Tree Capital, LLC's 49 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -38,340 | -100.0% | -0.03% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -11,500 | -100.0% | -0.04% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -50,500 | -100.0% | -0.18% | – |
| FXB | Exit | INVESCO CURNCYSHS BRIT PND Sbrit poun strl | $0 | – | -11,600 | -100.0% | -0.28% | – |
| CHMA | Exit | CHIASMA INC | $0 | – | -425,000 | -100.0% | -0.40% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -40,000 | -100.0% | -0.42% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -33,400 | -100.0% | -0.51% | – |
| INSM | Exit | INSMED INC | $0 | – | -200,000 | -100.0% | -0.91% | – |
| FXF | Exit | INVESCO CURNCYSHS SWISS FRANswiss franc | $0 | – | -52,000 | -100.0% | -0.94% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -175,000 | -100.0% | -1.02% | – |
| ARQL | Exit | ARQULE INC | $0 | – | -300,000 | -100.0% | -1.14% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -250,000 | -100.0% | -1.46% | – |
| DBVT | Exit | DBV TECHNOLOGIES S Asponsored adr | $0 | – | -750,000 | -100.0% | -1.53% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -65,000 | -100.0% | -1.60% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCput | $0 | – | -300,000 | -100.0% | -1.75% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INCcall | $0 | – | -350,000 | -100.0% | -1.84% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCcall | $0 | – | -150,000 | -100.0% | -2.06% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -150,000 | -100.0% | -2.29% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -1,250,000 | -100.0% | -2.32% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -575,000 | -100.0% | -2.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
| 13F-HR | 2021-11-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.